Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Transthyretin Amyloidosis Treatment Market Expected To Expand Between 2025 And 2029?
The transthyretin amyloidosis treatment market size has shown strong growth in recent years. It is forecast to increase from $4.59 billion in 2024 to $4.96 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. This historical growth can be credited to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, and collaboration in research.
The transthyretin amyloidosis treatment market size is projected to experience robust expansion in the coming years. It is anticipated to reach $6.83 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.3%. This expansion during the forecast period is primarily driven by an expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, and improved access to treatment. Furthermore, significant trends foreseen in this period include the emergence of combination therapies, strategic partnerships for drug development, a focus on targeting peripheral and cardiac manifestations, the implementation of patient education programs, and the incorporation of real-world evidence in treatment guidelines.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp
Which Factors And Drivers Are Influencing The Transthyretin Amyloidosis Treatment Market In 2025?
The transthyretin amyloidosis treatment market is expected to experience future growth, driven by an increase in research and development investments. Such investments represent financial resources directed towards advancing scientific understanding, developing new technologies, creating innovative products, and refining existing processes. Enhanced funding in research and development facilitates the discovery and creation of novel treatment approaches for transthyretin amyloidosis, encompassing new drugs, gene therapies, and precision medicine techniques, thereby offering patients more effective and precise therapeutic options. Illustratively, in December 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company focused on Vutrisiran, an ATTR amyloidosis treatment, raised its research and development investment to $883,015 in 2022 from $792,156 in 2021, showing an 11.49% increase. This upward trend in research and development investment will, therefore, propel the expansion of the transthyretin amyloidosis treatment market.
What Are The Major Segment Categories Driving The Transthyretin Amyloidosis Treatment Market Growth?
The transthyretin amyloidosis treatmentmarket covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN); Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis; Patisiran; Inotersen; Other Drugs
3) By Therapy: Targeted Therapy; Supportive Therapy; Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN; Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM; Moderate ATTR-CM; Severe ATTR-CM
How Are Emerging Market Trends Shaping The Transthyretin Amyloidosis Treatment Industry Landscape?
Leading companies in the transthyretin amyloidosis treatment market are focusing on developing innovative and specialized therapies, such as orphan drugs, to enhance patient outcomes and expand available treatment options. Eplontersen is an orphan drug specifically designed to treat transthyretin amyloidosis conditions, frequently receiving regulatory benefits to support its advancement. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, received The Food and Drug Administration (FDA) approval for a new drug application for Eplontersen, an experimental orphan drug intended for the treatment of familial transthyretin-mediated amyloid, which leads to progressive polyneuropathy. Eplontersen is a pharmaceutical agent developed to reduce the synthesis of transthyretin (TTR) protein, addressing both the hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA granted Eplontersen orphan drug designation in 2022.
Which Industry Leaders Are Driving Innovation Across The Transthyretin Amyloidosis Treatment Market?
Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Transthyretin Amyloidosis Treatment Industry Expansion?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Transthyretin Amyloidosis Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13129&type=smp
Browse Through More Reports Similar to the Global Transthyretin Amyloidosis Treatment Market 2025, By The Business Research Company
Pediatric Bladder Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report
Reversible Airway Diseases Treatment Global Market Report 2025
Urothelial Carcinoma Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model